“…It also should be noted that while a majority of the ERAS protocol initiatives implement each element simultaneously, individual element use and adherence is often not reported in the study. We have previously shown that after FDA approval of alvimopan, 13% of patients who were eligible did not receive it (11). This can be seen in the original alvimopan study as well, where only 83% of patients received the medication (12).…”